Activation of an Effective Immune Response after Yellow Fever Vaccination Is Associated with the Genetic Background and Early Response of IFN-γ and CLEC5A

The yellow fever vaccine (YF17DD) is highly effective with a single injection conferring protection for at least 10 years. The YF17DD induces polyvalent responses, with a TH1/TH2 CD4<sup>+</sup> profile, robust T CD8<sup>+</sup> responses, and synthesis of interferon-gamma (I...

Full description

Bibliographic Details
Main Authors: Tamiris Azamor, Andréa Marques Vieira da Silva, Juliana Gil Melgaço, Ana Paula dos Santos, Caroline Xavier-Carvalho, Lucia Elena Alvarado-Arnez, Leonardo Ribeiro Batista-Silva, Denise Cristina de Souza Matos, Camilla Bayma, Sotiris Missailidis, Ana Paula Dinis Ano Bom, Milton Ozorio Moraes, Patrícia Cristina da Costa Neves
Format: Article
Language:English
Published: MDPI AG 2021-01-01
Series:Viruses
Subjects:
Online Access:https://www.mdpi.com/1999-4915/13/1/96
id doaj-93477f11e43a4b728da8118ac46e7ebc
record_format Article
spelling doaj-93477f11e43a4b728da8118ac46e7ebc2021-01-13T00:05:17ZengMDPI AGViruses1999-49152021-01-0113969610.3390/v13010096Activation of an Effective Immune Response after Yellow Fever Vaccination Is Associated with the Genetic Background and Early Response of IFN-γ and CLEC5ATamiris Azamor0Andréa Marques Vieira da Silva1Juliana Gil Melgaço2Ana Paula dos Santos3Caroline Xavier-Carvalho4Lucia Elena Alvarado-Arnez5Leonardo Ribeiro Batista-Silva6Denise Cristina de Souza Matos7Camilla Bayma8Sotiris Missailidis9Ana Paula Dinis Ano Bom10Milton Ozorio Moraes11Patrícia Cristina da Costa Neves12Bio-Manguinhos/Fundação Oswaldo Cruz, Rio de Janeiro 21040-900, BrazilBio-Manguinhos/Fundação Oswaldo Cruz, Rio de Janeiro 21040-900, BrazilBio-Manguinhos/Fundação Oswaldo Cruz, Rio de Janeiro 21040-900, BrazilBio-Manguinhos/Fundação Oswaldo Cruz, Rio de Janeiro 21040-900, BrazilInstituto Oswaldo Cruz, Fundação Oswaldo Cruz, Rio de Janeiro 21040-900, BrazilNational Research Coordination, Universidad Privada Franz Tamayo, Cochabamba 4780, BoliviaMolecular Carcinogenesis Program—Research Coordination, Instituto Nacional do Câncer, Rio de Janeiro 20231-050, BrazilBio-Manguinhos/Fundação Oswaldo Cruz, Rio de Janeiro 21040-900, BrazilBio-Manguinhos/Fundação Oswaldo Cruz, Rio de Janeiro 21040-900, BrazilBio-Manguinhos/Fundação Oswaldo Cruz, Rio de Janeiro 21040-900, BrazilBio-Manguinhos/Fundação Oswaldo Cruz, Rio de Janeiro 21040-900, BrazilInstituto Oswaldo Cruz, Fundação Oswaldo Cruz, Rio de Janeiro 21040-900, BrazilBio-Manguinhos/Fundação Oswaldo Cruz, Rio de Janeiro 21040-900, BrazilThe yellow fever vaccine (YF17DD) is highly effective with a single injection conferring protection for at least 10 years. The YF17DD induces polyvalent responses, with a TH1/TH2 CD4<sup>+</sup> profile, robust T CD8<sup>+</sup> responses, and synthesis of interferon-gamma (IFN-γ), culminating in high titers of neutralizing antibodies. Furthermore, C-type lectin domain containing 5A (CLEC5A) has been implicated in innate outcomes in other flaviviral infections. Here, we conducted a follow-up study in volunteers immunized with YF17DD, investigating the humoral response, cellular phenotypes, gene expression, and single nucleotide polymorphisms (SNPs) of IFNG and CLEC5A, to clarify the role of these factors in early response after vaccination. Activation of CLEC5A<sup>+</sup> monocytes occurred five days after vaccination (DAV). Following, seven DAV data showed activation of CD4<sup>+</sup> and CD8<sup>+</sup>T cells together with early positive correlations between type II IFN and genes of innate antiviral response (STAT1, STAT2, IRF7, IRF9, OAS1, and RNASEL) as well as antibody levels. Furthermore, individuals with genotypes rs2430561 AT/AA, rs2069718 AG/AA (IFNG), and rs13237944 AC/AA (CLEC5A), exhibited higher expression of IFNG and CLEC5A, respectively. Together, we demonstrated that early IFN-γ and CLEC5A responses, associated with rs2430561, rs2069718, and rs13237944 genotypes, may be key mechanisms in the long-lasting immunity elicited by YF17DD.https://www.mdpi.com/1999-4915/13/1/96yellow fever vaccineinterferon gammaCLEC5A
collection DOAJ
language English
format Article
sources DOAJ
author Tamiris Azamor
Andréa Marques Vieira da Silva
Juliana Gil Melgaço
Ana Paula dos Santos
Caroline Xavier-Carvalho
Lucia Elena Alvarado-Arnez
Leonardo Ribeiro Batista-Silva
Denise Cristina de Souza Matos
Camilla Bayma
Sotiris Missailidis
Ana Paula Dinis Ano Bom
Milton Ozorio Moraes
Patrícia Cristina da Costa Neves
spellingShingle Tamiris Azamor
Andréa Marques Vieira da Silva
Juliana Gil Melgaço
Ana Paula dos Santos
Caroline Xavier-Carvalho
Lucia Elena Alvarado-Arnez
Leonardo Ribeiro Batista-Silva
Denise Cristina de Souza Matos
Camilla Bayma
Sotiris Missailidis
Ana Paula Dinis Ano Bom
Milton Ozorio Moraes
Patrícia Cristina da Costa Neves
Activation of an Effective Immune Response after Yellow Fever Vaccination Is Associated with the Genetic Background and Early Response of IFN-γ and CLEC5A
Viruses
yellow fever vaccine
interferon gamma
CLEC5A
author_facet Tamiris Azamor
Andréa Marques Vieira da Silva
Juliana Gil Melgaço
Ana Paula dos Santos
Caroline Xavier-Carvalho
Lucia Elena Alvarado-Arnez
Leonardo Ribeiro Batista-Silva
Denise Cristina de Souza Matos
Camilla Bayma
Sotiris Missailidis
Ana Paula Dinis Ano Bom
Milton Ozorio Moraes
Patrícia Cristina da Costa Neves
author_sort Tamiris Azamor
title Activation of an Effective Immune Response after Yellow Fever Vaccination Is Associated with the Genetic Background and Early Response of IFN-γ and CLEC5A
title_short Activation of an Effective Immune Response after Yellow Fever Vaccination Is Associated with the Genetic Background and Early Response of IFN-γ and CLEC5A
title_full Activation of an Effective Immune Response after Yellow Fever Vaccination Is Associated with the Genetic Background and Early Response of IFN-γ and CLEC5A
title_fullStr Activation of an Effective Immune Response after Yellow Fever Vaccination Is Associated with the Genetic Background and Early Response of IFN-γ and CLEC5A
title_full_unstemmed Activation of an Effective Immune Response after Yellow Fever Vaccination Is Associated with the Genetic Background and Early Response of IFN-γ and CLEC5A
title_sort activation of an effective immune response after yellow fever vaccination is associated with the genetic background and early response of ifn-γ and clec5a
publisher MDPI AG
series Viruses
issn 1999-4915
publishDate 2021-01-01
description The yellow fever vaccine (YF17DD) is highly effective with a single injection conferring protection for at least 10 years. The YF17DD induces polyvalent responses, with a TH1/TH2 CD4<sup>+</sup> profile, robust T CD8<sup>+</sup> responses, and synthesis of interferon-gamma (IFN-γ), culminating in high titers of neutralizing antibodies. Furthermore, C-type lectin domain containing 5A (CLEC5A) has been implicated in innate outcomes in other flaviviral infections. Here, we conducted a follow-up study in volunteers immunized with YF17DD, investigating the humoral response, cellular phenotypes, gene expression, and single nucleotide polymorphisms (SNPs) of IFNG and CLEC5A, to clarify the role of these factors in early response after vaccination. Activation of CLEC5A<sup>+</sup> monocytes occurred five days after vaccination (DAV). Following, seven DAV data showed activation of CD4<sup>+</sup> and CD8<sup>+</sup>T cells together with early positive correlations between type II IFN and genes of innate antiviral response (STAT1, STAT2, IRF7, IRF9, OAS1, and RNASEL) as well as antibody levels. Furthermore, individuals with genotypes rs2430561 AT/AA, rs2069718 AG/AA (IFNG), and rs13237944 AC/AA (CLEC5A), exhibited higher expression of IFNG and CLEC5A, respectively. Together, we demonstrated that early IFN-γ and CLEC5A responses, associated with rs2430561, rs2069718, and rs13237944 genotypes, may be key mechanisms in the long-lasting immunity elicited by YF17DD.
topic yellow fever vaccine
interferon gamma
CLEC5A
url https://www.mdpi.com/1999-4915/13/1/96
work_keys_str_mv AT tamirisazamor activationofaneffectiveimmuneresponseafteryellowfevervaccinationisassociatedwiththegeneticbackgroundandearlyresponseofifngandclec5a
AT andreamarquesvieiradasilva activationofaneffectiveimmuneresponseafteryellowfevervaccinationisassociatedwiththegeneticbackgroundandearlyresponseofifngandclec5a
AT julianagilmelgaco activationofaneffectiveimmuneresponseafteryellowfevervaccinationisassociatedwiththegeneticbackgroundandearlyresponseofifngandclec5a
AT anapauladossantos activationofaneffectiveimmuneresponseafteryellowfevervaccinationisassociatedwiththegeneticbackgroundandearlyresponseofifngandclec5a
AT carolinexaviercarvalho activationofaneffectiveimmuneresponseafteryellowfevervaccinationisassociatedwiththegeneticbackgroundandearlyresponseofifngandclec5a
AT luciaelenaalvaradoarnez activationofaneffectiveimmuneresponseafteryellowfevervaccinationisassociatedwiththegeneticbackgroundandearlyresponseofifngandclec5a
AT leonardoribeirobatistasilva activationofaneffectiveimmuneresponseafteryellowfevervaccinationisassociatedwiththegeneticbackgroundandearlyresponseofifngandclec5a
AT denisecristinadesouzamatos activationofaneffectiveimmuneresponseafteryellowfevervaccinationisassociatedwiththegeneticbackgroundandearlyresponseofifngandclec5a
AT camillabayma activationofaneffectiveimmuneresponseafteryellowfevervaccinationisassociatedwiththegeneticbackgroundandearlyresponseofifngandclec5a
AT sotirismissailidis activationofaneffectiveimmuneresponseafteryellowfevervaccinationisassociatedwiththegeneticbackgroundandearlyresponseofifngandclec5a
AT anapauladinisanobom activationofaneffectiveimmuneresponseafteryellowfevervaccinationisassociatedwiththegeneticbackgroundandearlyresponseofifngandclec5a
AT miltonozoriomoraes activationofaneffectiveimmuneresponseafteryellowfevervaccinationisassociatedwiththegeneticbackgroundandearlyresponseofifngandclec5a
AT patriciacristinadacostaneves activationofaneffectiveimmuneresponseafteryellowfevervaccinationisassociatedwiththegeneticbackgroundandearlyresponseofifngandclec5a
_version_ 1724339648363233280